Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04866771 · ClinicalTrials.gov registry record · NA
Remotely Supervised tDCS for Slowing ALS Disease Progression
A NA study of Amyotrophic Lateral Sclerosis (ALS), sponsored by University of Illinois at Chicago.
- Completed
- Registry status
- NA
- Development phase
- 14
- Enrollment target
- 1
- Study location
NCT04866771: Completed NA study of Amyotrophic Lateral Sclerosis (ALS), sponsored by University of Illinois at Chicago.
NCT04866771 is a NA study of Amyotrophic Lateral Sclerosis (ALS) that has completed, run by University of Illinois at Chicago. The registered enrollment target is 14 participants, below the 301-participant average among 18 other Amyotrophic Lateral Sclerosis (ALS) trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04866771, a NA study of Amyotrophic Lateral Sclerosis (ALS), has completed, sponsored by University of Illinois at Chicago.
- COMPLETED
- Registry status
- NA
- Development phase
- 14 participants
- Enrollment target
- 1
- Study location
Study Summary
Most ALS care is centered on patient support and symptom management, making rehabilitation an integral aspect for slowing disease progression, prolonging life span, and increasing quality of life. Brain stimulation has been increasingly explored as a promising neuromodulatory tool to prime motor function in several neurological disorders. We propose a novel mechanism using remotely supervised brain stimulation to preserve motor function in individuals with ALS. This project will also aim to explore the effectiveness of brain stimulation on upper and lower motor neuron mechanisms in individuals with ALS.
Primary Outcome
This questionnaire evaluates function over time and disease progression in ALS patients with questions related to daily activities such as speech, swallowing, walking, etc. Scores range between 0-48 with higher scores corresponding to more function being retained.
Conditions Studied
Interventions
- OTHER Transcranial Direct Current Stimulation (tDCS)
- OTHER Sham tDCS + anodal tDCS
Study Locations (1)
Illinois
- Brain Plasticity Lab - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2021-08-27 |
| Est. Completion | 2025-01-01 |
| Phase | NA |
What the finished NCT04866771 record still lists
NCT04866771 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 14 participants, a relatively small participant target, below the 301-participant average among 18 other Amyotrophic Lateral Sclerosis (ALS) trials with a reported enrollment target (95% lower).
The record links to 1 condition, with Amyotrophic Lateral Sclerosis (ALS) appearing as the primary indexed condition, and to 2 interventions - of which Transcranial Direct Current Stimulation (tDCS) is the first listed.
NCT04866771 reports a single indexed study location in Illinois.
Frequently Asked Questions
What is clinical trial NCT04866771 about?
NCT04866771 is a clinical study titled "Remotely Supervised tDCS for Slowing ALS Disease Progression". Most ALS care is centered on patient support and symptom management, making rehabilitation an integral aspect for slowing disease progression, prolonging life span, and increasing quality of life. Brain stimulation has been increasingly explored as a promising neuromodulatory tool to prime motor fun...
What is the current status of trial NCT04866771?
This trial is currently completed. It is a NA study. The enrollment target is 14 participants. The study started on 2021-08-27. Estimated completion is 2025-01-01.
What conditions does trial NCT04866771 study?
This clinical trial studies the following conditions: Amyotrophic Lateral Sclerosis (ALS).
What interventions are being tested in trial NCT04866771?
The interventions under investigation include: Transcranial Direct Current Stimulation (tDCS) (OTHER), Sham tDCS + anodal tDCS (OTHER).
Who is sponsoring clinical trial NCT04866771?
This trial is sponsored by University of Illinois at Chicago, which has 430 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04866771 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Amyotrophic Lateral Sclerosis (ALS)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04866771's enrollment target sits among peer trials
14 18th of 18 higher than 1 of 18 other Amyotrophic Lateral Sclerosis (ALS) trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Amyotrophic Lateral Sclerosis (ALS) trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Investigating the Impact of Electrical Stimulation on Facial Pain, Jaw Movement and Oral Health in People With Motor Neuron Disease.
RECRUITING · NA
-
Examining Interactions Between PALS and Caregivers
RECRUITING · NA
-
Humanitarian Device Exemption Post-Approval Study of NeuRx Diaphragm Pacing System for Amyotrophic Lateral Sclerosis
COMPLETED · NA
-
Brain and Nerve Stimulation for Hand Muscles in Spinal Cord Injury and ALS
COMPLETED · NA
-
Healing ALS Registry Observational Study (HAROS)
RECRUITING
-
Mitochondrial Capacity Boost in ALS (MICABO-ALS) Trial
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02523092 · 14 participants · Phase 4
Use of CXCL9 as a Biomarker of Acthar Efficacy
- NCT04263285 · 14 participants · NA
Treatment of Depression Post-SCI
- NCT04743271 · 14 participants · NA
Food and Circadian Timing
- NCT05065671 · 14 participants · Phase 1
Microbiome Derived Metabolism and Pharmacokinetics
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT06358040 · started 2026-10 · NA
Opioid Dispenser for Microdiscectomy/Laminectomy